IQVIA Biotech Thought Leadership

  1. Future Forward View For Biotech Companies 7/26/2021

    The pandemic has forced the biotech industry to quickly adapt and, as a result, is fueling the modernization of clinical trials. This article will review the biotech perspective of modern clinical trials and explore what the next normal may look like.

  2. Helping Non-U.S. Based Biotechs Navigate Entry Into The U.S. Clinical Development Market 8/19/2021

    Increasingly, non-U.S. based companies are looking to bring their innovative investigational products to the U.S. for clinical development. Clearing the U.S. FDA not only ensures access to the largest market but also may provide a smoother path to marketing approval in other countries and markets.

  3. Moving Forward In Immuno-Dermatology: Clinical Trial Considerations 8/19/2021

    The global commercial dermatology market is estimated to reach $33.7 billion by 2022. With this momentum and the continued need for safe and effective dermatology treatments, it’s important to understand the strategic needs of clinical trials using novel immuno-dermatology agents.

  4. Considerations In Dermatology Gene Therapy Development 8/19/2021

    Gene therapies now offer a new trajectory to address the cause of the disease, rather than simply alleviating symptoms. See how gene therapy is changing the trajectory of dermatology therapeutics by direct targeting of mutations.

  5. Optimizing Immuno-Oncology Clinical Trials For Biotech Companies 3/3/2021

    For biotech companies developing an immuno-oncology (IO) therapy, the complexity of oncology clinical trials takes on new dimensions. Review the current IO landscape and considerations for biotech companies preparing for IO studies.

     
  6. Optimize Your Dermatology Study With A Data-Informed Protocol Assessment 8/19/2021

    Nearly 60 percent of clinical trials have protocol amendments, leading to significant timeline delays and additional cost. Discover how four data-driven protocol design analyses can increase the chances of study success in dermatology clinical trials.

  7. Looking Ahead: The Future Of Cell Therapy In Oncology 8/19/2021

    The future is promising for the field of cell therapy. However, there are still challenges to overcome, including the length of time required to manufacture cell therapies, high costs, and logistical challenges.

  8. Applying Virtual Approaches To Dermatology Trials

    Explore how to integrate virtual approaches into the design and delivery of dermatology trials – to mitigate study risks and enhance patient engagement.

  9. Reducing Patient Burden: Considerations For Virtual Dermatology Trials 8/19/2021

    While it is not practical to think every dermatology trial can be 100% virtual, it is possible to customize and incorporate virtual aspects into these programs with a hybrid approach.

  10. The Emerging Pharmaco's Dilemma: Make A Deal…Or Not? 7/26/2021

    IQVIA Biotech analyzed the approaches of companies that launched products for the first time to understand their funding/commercialization strategies. This white paper presents the results of this analysis and discusses the implications for the three types of players involved.